L\u2019Agence europ\u00e9enne des m\u00e9dicaments (EMA), agence de l\u2019Union europ\u00e9enne bas\u00e9e \u00e0 Amsterdam, a publi\u00e9 le 5 octobre 2026 un projet de \u00ab reflection paper \u00bb sur les aspects m\u00e9thodologiques des essais cliniques de confirmation de type plateforme (\u00ab confirmatory platform trials \u00bb). Ce document est \u00e9labor\u00e9 par le Committee for Medicinal products for Human Use (CHMP), via son Methodology Working Party, et vise \u00e0 encadrer et harmoniser la conduite de ces essais en phase de confirmation pour les m\u00e9dicaments \u00e0 usage humain.<\/p>\n
Le texte se concentre sur plusieurs questions m\u00e9thodologiques cl\u00e9s propres aux essais plateformes : la pr\u00e9-sp\u00e9cification des plans d\u2019\u00e9tude, les modalit\u00e9s de randomisation, la gestion des bras de contr\u00f4le et les questions de multiplicit\u00e9. Il traite notamment de la mani\u00e8re de d\u00e9finir \u00e0 l\u2019avance les hypoth\u00e8ses, les adaptations possibles du protocole et les r\u00e8gles statistiques, afin d\u2019assurer la robustesse des r\u00e9sultats et leur acceptabilit\u00e9 r\u00e9glementaire.<\/p>\n
Sur la randomisation, le document aborde les choix de ratios et probabilit\u00e9s d\u2019allocation entre bras de traitement, l\u2019usage \u00e9ventuel de randomisation en plusieurs \u00e9tapes (\u00ab multi-stage randomisation \u00bb), ainsi que la possibilit\u00e9 de re-randomiser des participants au cours de l\u2019essai. Concernant les groupes t\u00e9moins, il distingue l\u2019usage de contr\u00f4les communs \u00e0 plusieurs bras de traitement et la question de l\u2019utilisation de contr\u00f4les concurrents ou non concurrents dans le temps, th\u00e8me sensible pour l\u2019interpr\u00e9tation des r\u00e9sultats et la comparabilit\u00e9 des donn\u00e9es.<\/p>\n
Le projet a \u00e9t\u00e9 approuv\u00e9 au sein du Methodology Working Party le 20 ao\u00fbt 2026, puis adopt\u00e9 par le CHMP pour consultation publique le 5 octobre 2026. La consultation publique est ouverte du 19 octobre 2026 au 31 janvier 2027. Les commentaires doivent \u00eatre transmis via un formulaire en ligne EUSurvey, avec un appui technique pr\u00e9vu par le support EUSurvey. Les principaux acteurs mentionn\u00e9s sont donc l\u2019EMA, le CHMP et son Methodology Working Party, dans le cadre de la r\u00e9gulation europ\u00e9enne du m\u00e9dicament.<\/p>\n
Ce document s\u2019inscrit dans l\u2019\u00e9volution des cadres m\u00e9thodologiques pour les essais cliniques complexes, en particulier ceux int\u00e9grant plusieurs traitements et adaptations, et pr\u00e9sente un int\u00e9r\u00eat potentiel pour le suivi des politiques de sant\u00e9 et de recherche clinique, notamment en mati\u00e8re d\u2019\u00e9valuation des m\u00e9dicaments et de conception d\u2019essais pouvant impliquer des patients dans diff\u00e9rents \u00c9tats membres de l\u2019UE, dont la France. Toutefois, le texte disponible est une version de travail (draft) soumise \u00e0 consultation, susceptible d\u2019\u00eatre modifi\u00e9e avant adoption finale. (contenu r\u00e9sum\u00e9 en fran\u00e7ais par l’IA)\u00a0\u200bLire la Suite<\/a><\/p>","protected":false},"excerpt":{"rendered":" L\u2019Agence europ\u00e9enne des m\u00e9dicaments (EMA), agence de l\u2019Union europ\u00e9enne bas\u00e9e \u00e0 Amsterdam, a publi\u00e9 le 5 octobre 2026 un projet de \u00ab reflection paper \u00bb sur les aspects m\u00e9thodologiques des […]<\/p>\n","protected":false},"author":1,"featured_media":17698,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"default","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","ast-disable-related-posts":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"footnotes":""},"categories":[7],"tags":[257,227,226],"class_list":["post-21411","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-medicaments-et-produits-de-sante","tag-ema","tag-ia","tag-sources-etrangeres"],"_links":{"self":[{"href":"https:\/\/veilles-affaires-sociales.fr\/index.php?rest_route=\/wp\/v2\/posts\/21411","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/veilles-affaires-sociales.fr\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/veilles-affaires-sociales.fr\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/veilles-affaires-sociales.fr\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/veilles-affaires-sociales.fr\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=21411"}],"version-history":[{"count":0,"href":"https:\/\/veilles-affaires-sociales.fr\/index.php?rest_route=\/wp\/v2\/posts\/21411\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/veilles-affaires-sociales.fr\/index.php?rest_route=\/wp\/v2\/media\/17698"}],"wp:attachment":[{"href":"https:\/\/veilles-affaires-sociales.fr\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=21411"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/veilles-affaires-sociales.fr\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=21411"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/veilles-affaires-sociales.fr\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=21411"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}